SF 361171-P

The Evolving Treatment Landscape of AMD and DME: Updates and Insights for Pharmacists (Recorded Podcast)

Key References:

Anzueto A, Kaplan A. Dual bronchodilators in chronic obstructive pulmonary disease: evidence from randomized controlled trials and real-world studies. Elsevier. 2020. Accessed February 23, 2023. https://doi.org/10.1016/j.yrmex.2020.100016

Brennan Z. Real-world evidence: lessons learned from an FDA pilot show the limits of emulating RCTs. Endpoints News. May 16, 2022. Accessed February 23, 2023. https://endpts.com/real-world-evidence-lessons-learned-from-an-fda-pilot-show-the-limits-of-emulating-rcts/

Hahn P, Raef S, eds. Preferences and Trends (PAT) Survey. American Society of Retina Specialists. 2021. Accessed February 23, 2023. https://asrs.org/content/documents/2021-global-trends-survey-highlights.pdf

Ho AC, Kleinman DM, Lum FC, et al. Baseline visual acuity at wet AMD diagnosis predicts long-term vision outcomes: an analysis of the IRIS registry. *Ophthalmic Surg Lasers Imaging Retina*. 2020;51(11):633-639. doi: 10.3928/23258160-20201104-05

Holekamp MN, Campochiaro PA, Chang MA, et al. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. *Ophthalmology*. 2022;129(3):295-307. doi: 10.1016/j.ophtha.2021.09.016

Huang N, Oellers P. Emerging treatments for neovascular AMD. *Retina Today*. 2019. Accessed February 23, 2023. https://retinatoday.com/articles/2019-may-june/emerging-treatments-for-neovascular-amd

Khurana RN, Rahimy E, Joseph WA, et al. Extended (every 12 weeks or longer) dosing interval with intravitreal aflibercept and ranibizumab in neovascular age-related macular degeneration: post hoc analysis of VIEW trials. *Am J Ophthalmol.* 2019;200:161-168. doi: 10.1016/j.ajo.2019.01.005

Nguyen QD, Das A, Do DV, et al. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. *Ophthalmology*. 2020;127(7):963-976. doi: 10.1016/j.ophtha.2019.12.031

Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. *Ophthalmic Surg Lasers Imaging*. 2005;36(4):331-335.

Schimdt-Erfueth U, Kaiser PK, Korobelnik J-F, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. *Ophthalmology*. 2014;121(1):193-201. doi: 10-1016/j.ophtha.2013.08.011

Steinbrock R. The price of sight—ranibizumab, bevacizumab, and the treatment of macular degeneration. *N Engl J Med*. 2006;355(14):1409-1412. doi: 10.1056/NEJMp068185

Ying G, Maguire MG, Daniel E, et al. Association of baseline characteristics and early vision response with 2-year vision outcomes in the Comparison of AMD Treatment Trials (CATT). *Ophthalmology*. 2015;122(12):2523-2531.e1. doi: 10-1016/j.ophtha.2015.08.015